About Jade Biosciences, Inc.

Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases. It develops JADE101, a monoclonal antibody to block the A PRoliferation Inducing Ligand protein, which is in phase 1 clinical trial. The company also develops JADE201 and JADE-003, which are in preclinical development stage. Jade Biosciences, Inc. has a collaboration agreement with Paragon Therapeutics, Inc. Jade Biosciences, Inc. is based in Waltham, Massachusetts.

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Employees: 55
Price: $14.71
Previous close: $14.71
Market capitalization: $895.25M
Volume: 1,464,714
P/E ratio: -5.35
52-week low: $7.58
52-week high: $28.00

Additional performance and financial-statement views load in the interactive application.

Market information is provided for research and visualization and is not investment advice.